RPI 78M

Drug Profile

RPI 78M

Alternative Names: Alpha-cobratoxin-derived peptide; Alpha-Immunokine; Receptin; RPI-78M

Latest Information Update: 28 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bio Therapeutics
  • Developer ReceptoPharm
  • Class Antivirals; Immunotherapies; Peptides
  • Mechanism of Action Nicotinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple sclerosis
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II/III Adrenomyeloneuropathy
  • Phase I Multiple sclerosis
  • No development reported Herpes simplex virus infections
  • Discontinued Rabies

Most Recent Events

  • 28 Jun 2018 No recent reports of development identified for phase-I development in Adrenomyeloneuropathy in USA (Buccal, Spray)
  • 28 Jun 2018 No recent reports of development identified for phase-I development in Herpes-simplex-virus-infections in USA (SC, Injection)
  • 22 Jun 2018 RPI 78M is available for licensing as of 22 Jun 2018 (ReceptoPharm website, June 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top